Comparison of HER2 status in breast cancer patients using CISH and immunohistochemical protocols

Kubelka-Sabit, Katerina; Filipovski, Vanja; Jasar, Dzengis

doi:10.1097/01.pat.0000454287.62515.99

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In agreement with our study, Hlavac et al showed that ABCC12 gene expression significantly increased in post-treatment breast tumors (21). Kubelka-Sabit et al evaluated HER-2 status in BC patients using CISH and IHC methods and showed HER-2 gene amplification in all 3+ patients, whereas 1+ patients did not show HER-2 gene amplification (22). Our findings are in agreement with this result.…”

Section: Discussionsupporting

confidence: 93%

Evaluation of Additional ABCC12 Gene Expression Character in Breast Cancer Samples Using Formal Diagnostic Profile

2019

View full text Add to dashboard Cite

Background: Breast cancer (BC) is one of the most common cancers among women and is the main cause of cancer-related mortalities in the female population. The main cause of BC is not fully understood yet; however, many genes have been identified as risk factors that increase susceptibility to this disease. Objectives: The aim of this study was to evaluate the expression of ABCC12 gene in patients with ductal breast carcinoma and its relationship with other biomarkers including estrogen receptor (ER), progesterone receptor (RP) and human epidermal growth factor receptor 2 (HER-2). Methods: This study included nine women diagnosed with ductal breast carcinoma as cases and five healthy women as controls. RNA extraction from breast tissue and cDNA synthesis were performed, and the expression of ABCC12 gene was evaluated using the real time polymerase chain reaction (PCR) method. After preparing formalin-fixed paraffin-embedded breast tissues, immunohistochemical evaluation of these samples and chromogenic in situ hybridization (CISH) of ER, PR and HER-2 were performed. Results: The obtained results showed that the expression of ABCC12 gene in all the breast cancer tissues was 3.74 times higher than in controls (P = 0.007). Also, the expression of ABCC12 gene increased by 3.94 times in luminal B (P = 0.002), 3.54 times in HER-2 (1+) (P = 0.0006), 3.86 times in ER (+) (P = 0.002) and 3.63 times in PR (+) (P = 0.0005). Conclusions: Our study showed that the evaluation of the ABCC12 gene expression as a one of multi-drug resistance protein members can be used as a prognostic factor to identify the stages of BC and its therapeutic approaches.

show abstract

Section: Discussionsupporting

confidence: 93%